We report an adult patient with ATC and a biopsied tumor metastasis harboring a CCDC6-RET gene fusion who responded dramatically to LOXO-292, a highly selective RET inhibitor currently in clinical development. This evidence concerns the gene CCDC6 and neoplasm.